Tamil Nadu's New Player: Sthree Chemicals' ₹15 Crore API Plant in Ranipet

Sthree Chemicals Private Limited is set to make significant strides in the pharmaceutical sector with its upcoming API (Active Pharmaceutical Ingredients) and intermediates manufacturing plant. Situated in the strategic location of the SIPCOT Industrial Complex in Mugundharayapuram, Walajapet, Ranipet, Tamil Nadu, this project, with an estimated cost of ₹15.018 Crore, is poised to bolster India's capabilities in producing critical pharmaceutical components. With a planned production capacity of 473.3 KLD (Kiloliters per Day), Sthree Chemicals aims to contribute substantially to the healthcare and pharmaceutical industries by ensuring a steady domestic supply of essential APIs and intermediates.

The product lineup slated for manufacturing at this facility addresses a wide array of medical conditions, ranging from irritable bowel syndrome with Alosetron Hydrochloride to hereditary tyrosinemia type 1 with Nitisinone. Other notable products include Atropine Sulfate Monohydrate for anti-spasmodic purposes, Brivudine as an anti-viral, and Carglumic Acid for treating hyperammonemia, among others. This diverse portfolio not only demonstrates Sthree Chemicals’ commitment to contributing to global health but also positions the company as a key player in the pharmaceutical manufacturing sector.

This initiative is expected to bring multiple benefits, primarily by enhancing India's self-reliance in the pharmaceutical domain. By increasing the domestic production of essential APIs and intermediates, the project aims to reduce the country’s dependency on imports, which is crucial for maintaining a stable supply chain in the healthcare sector. Furthermore, the increased availability of these critical components could lead to more affordable and accessible medications for patients across the country.

News by Rahul Yelligetti